Massachusetts General Hospital: Melanoma trials

The registry lists 14 Melanoma studies with Massachusetts General Hospital as lead sponsor. 1 are open to participants now and 5 have results posted.

Phase 1 3Phase 2 5No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Cryoablation+Ipilimumab+Nivolumab in MelanomaRecruitingNCT05779423Phase 2
• INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.TerminatedNCT03272464Phase 1Results posted
• Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in MelanomaActive, not recruitingNCT03149029Phase 2Results posted
• A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or ImmunotherapyCompletedNCT02431572Not applicableResults posted
• Utility of Novel BRAF Test for MelanomaCompletedNCT01840527Results posted
• Combined BRAF-Targeted Therapy & Immunotherapy for MelanomaTerminatedNCT01754376Phase 2Results posted
• Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment DiscontinuationActive, not recruitingNCT06146920Not applicable
• PD-1 Antibody Therapy + Infliximab for Metastatic MelanomaActive, not recruitingNCT05034536Phase 2
• Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced CancerCompletedNCT04670445Not applicable
• Infliximab for Treatment of Immune Checkpoint Inhibitor ColitisActive, not recruitingNCT04305145Phase 2
• GI Complications in Cancer Immunotherapy PatientsStatus unknownNCT02784366
• Ensuring Communication in Hospice by Oncology Study (ECHO)CompletedNCT02069769Not applicable
• Leflunomide+Vemurafenib in V600 Mutant Met. MelanomaTerminatedNCT01611675Phase 1
• An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant MelanomaCompletedNCT01078961Phase 1